Cambrex Corporation

Life Science/Pharmaceutical Industry/Animal Pharmaceuticals

East Rutherford, NJ, United States

Description

Cambrex Corporation, founded in 1981 and headquartered in East Rutherford, New Jersey, is a privately owned company with approximately 2,200 employees. It operates as a leading global contract development and manufacturing organization (CDMO) specializing in small molecule drug development and manufacturing. Cambrex primarily serves B2B clients across various industries requiring pharmaceutical ingredient solutions. The company’s offerings include drug development, analytical services, manufacturing, and formulation development, supporting pharmaceutical and biotechnology companies throughout the product lifecycle. With extensive industry expertise and a broad service portfolio, Cambrex plays a key role in the pharmaceutical supply chain, facilitating the development and commercialization of small molecule drugs.

Experteer Insights

Locations 10

Vacancies 3

Experteer Briefing

Company Trajectory

Cambrex Corporation, headquartered in East Rutherford, New Jersey, has evolved significantly since its founding in 1981. Starting as a fine chemical manufacturer, Cambrex steadily expanded its capabilities and presence in the life sciences sector over the decades. Through strategic pivots and market expansions, the company transitioned into a global contract development and manufacturing organization (CDMO) with a keen focus on small molecule drug development and manufacturing. Cambrex has continually grown its operations and workforce, positioning itself as a reliable partner for pharmaceutical companies worldwide.

Financial Setup

Currently, Cambrex operates as a privately owned enterprise with a workforce of around 2,200 employees. The company serves a B2B customer base, reflecting its orientation toward supporting pharmaceutical developers from across the globe. Over time, Cambrex has built a financial structure rooted in service-based revenue streams associated with drug development and contract manufacturing. Continuous investments in new capabilities and acquisitions have underpinned its growth and sustained financial health.

Development & Outlook

Cambrex offers a comprehensive suite of CDMO services, including drug substance development and manufacturing, drug product services, and analytical testing. Its expertise ranges from small molecule APIs and process development to oral solids, sterile injectables, and complex formulations. The company is known for its robust approach to method development, validation, and stability testing. Cambrex’s ongoing investments in facility and technology expansion underscore its commitment to innovation and maintaining industry relevance. Looking ahead, the company continues to drive growth by enhancing its service offerings and expanding its footprint in the pharmaceutical outsourcing market.